nice_new_london_office_internal_3_web

Bayer’s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer at risk of metastasis

pharmafile | October 23, 2020 | News story | Medical Communications, Sales and Marketing Bayer, NCIE, Nubeqa, pharma 

NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of hormone-relapsed prostate cancer in adults at high-risk of developing metastasis.

The condition sees around 48,000 new cases per year in the UK, with one in three patients developing metastases within two years.

Phase 3 data supporting the decision indicated that the Nubeqa combo improved metastasis-free survival by a median of 40.4 months, compared to 18.4 months with placebo combined with ADT, meeting the study’s primary goal.

The combo also reduced the risk of death by 31% compared to the placebo group, with an overall survival rate of 83% after three years compared to 77% respectively across the two treatment groups.

“NICE’s positive recommendation of darolutamide helps to address an unmet need for hormone-relapsed non-metastatic prostate cancer or, as it is known, non-metastatic castration-resistant prostate cancer (nmCRPC) patients,” said Professor Amit Bahl, Consultant Clinical Oncologist, University Hospitals Bristol NHS Foundation Trust. “A new treatment option that significantly delays the development of metastases whilst also prolonging life, with a generally manageable safety profile is imperative for men diagnosed with nmCRPC, as we aim to ensure minimal disruption to their treatment and day-to-day lives. Men with nmCRPC typically have no symptoms so it’s critical that they can be treated early to delay the prostate cancer from spreading.”

Matt Fellows

Related Content

Bayer and Aignostics to collaborate for AI oncology research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content